Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Sw sn

532 views

Published on

PDT for choroidal hemangioma. Case presentation and review of literature

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Sw sn

  1. 1. Management of choroidal hemangioma By Hany EL-Defrawy, MVR Fellow BEH
  2. 2. Diffuse choroidal hemangioma Rare Sporodic Neuro-Oculocutaneous disorder Facial nevus flammeus Buphthalmos Diffuse choroidal hemangioma (Tomato-Catsup) Leptomeningeal hemangiomatosis Epilepsy MR Hemiplegia
  3. 3. Circumscribed choroidal hemangioma Uncommon, benign vascular tumour Discrete, smooth round orange red mass Macular and peripapillary region
  4. 4. Causes of visual loss1. Refractive error2. Foveal distortion3. Transudative leakage and CMO4. Serous Retinal detachment with secondary photoreceptor damage
  5. 5. Diagnosis Ultrasongraphy FFA OCT MRI
  6. 6. When to treat? Visual acuity potential Extent of detachment
  7. 7. Why challenging? Limitedtherapeutic options (Why?) Surgery (Dangerous)
  8. 8.  Size Location Associated SRF
  9. 9. Armamentarium External beam radiation therapy (5 observational studies) Proton beam therapy Brachytherapy Photodynamic therapy Cryotherapy Transpupillary thermotherapy Anti VEGF IVTA Combined therapy
  10. 10. Radiation Cataract Radiation optic neuropathy Retinopathy Increase incidence of osteosarcoma Chorioretinal atrophy
  11. 11. Other modalities Plaque Brachytherapy1. Murthy 20052. Zografos 1996 Proton Beam Stereotactic therapy (Gamma Knife) Anti VEGF PDT
  12. 12. PDT Anand 2003 Bains et al 2004 Singh et al 2005 Huiskamp 2005 Tsipursky
  13. 13. Ophthalmology 2009;116:100-105
  14. 14.  31 patients with CCH and symptoms Underwent PDT IV Verteporfin 6 mg/m 2 689nm laser 15 min laser 50j/cm 2 83 sec exposure 1-4 treatment Follow up 12 month
  15. 15.  Primary end point1. Absence of exudative RD at 12 month follow up (FFA,OCT, Ophthalmoscopy) Secondary endpoint1. Visual acuity2. Tumour thickness decrease3. Adverse events
  16. 16.  Inclusion criteria1. 18 with CCH height 5 mm and diameter 12 mm2. Exudative RD affecting the fovea3. No cataract within last 2 months Exclusion criteria1. NYHA Class III-IV2. Porphyria3. Liver disease4. Active hepatitis
  17. 17. Results 82.8% 1 session 13.8% 2 sessions 3.4% 3 sessions Visual acuity increased mean 20/60 to 20/ 35 CMO regressed and Exudative RD disappeared in all except 2 cases. CCH thickness decreased from 3 to 1.7 mm Visual fields showed resolution of central scotomas No adverse events
  18. 18. Am J ophthalmol 2010
  19. 19.  Retrospective study of 14 patients with symptommatic circumscribed choroidal hemangioma who underwent PDT± IVTA  Shao Huang, James Fabian etal. Optometery and visual science , 2009.
  20. 20.  Symptomatic visual loss Exudative Detachment Macular edema Subfoveal fluid Tumour encroaching to within 2 mm of the fovea.
  21. 21.  7.5 mm spot size Overlapping spots 83 sec IVTA (0.1ml of 40 mg/ml) Baseline VA IOP Macular thickness 10 eyes PDT 4 PDT and IVTA
  22. 22. Conclusion Optimal treatment settings remains a matter of debate for CCH Variable number of spots Ranging Spot size (2500-7700µ) Ranging duration (60-83sec) Overlapping vs non overlapping spots Number of treatment sessions

×